Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | Efgartigimod - (ADHERE) | Chronic inflammatory demyelinating polyneuropathy (CIDP) | BLA Filing | Data Released | Intravenous | Neurology |
| Harmony Biosciences Holdings Inc. | Zygel (ZYN002) - (BELIEVE 1) | Developmental and Epileptic Encephalopathies (DEE) | Phase 2 | Trial Discontinued | Transdermal | Neurology |
| Harmony Biosciences Holdings Inc. | Zygel (ZYN002) - (INSPIRE) | 22q11.2 Deletion Syndrome | Phase 2 | Ongoing | Transdermal | Genetic Disorder |
| Harmony Biosciences Holdings Inc. | Zygel (ZYN002) - (RECONNECT) | Fragile X syndrome | Phase 3 | Trial Discontinued | Transdermal | Genetic Disorder |
| Harmony Biosciences Holdings Inc. | WAKIX - (Pitolisant GR) | GI symptoms; | NDA Filing | Ongoing | Oral | Gastroenterology |
| Harmony Biosciences Holdings Inc. | WAKIX (pitolisant HD) - (ONSTRIDE 1) | Narcolepsy | Phase 3 | Ongoing | oral | Neurology |
| Harmony Biosciences Holdings Inc. | Zygel (ZYN002) - (BRIGHT) | Autism Spectrum Disorder (ASD) | Phase 3 | Trial Discontinued | Transdermal | Psychiatric |
| Harmony Biosciences Holdings Inc. | WAKIX (pitolisant) - (TEMPO) | Excessive daytime sleepiness associated with Prader-Willi Syndrome (PWS) | Phase 3 | Ongoing | oral | Genetic Disorder |
